Last reviewed · How we verify
Lipid-lowering drug
A lipid-lowering drug that reduces blood cholesterol and triglyceride levels to prevent cardiovascular disease.
A lipid-lowering drug that reduces blood cholesterol and triglyceride levels to prevent cardiovascular disease. Used for Hyperlipidemia, Cardiovascular disease prevention.
At a glance
| Generic name | Lipid-lowering drug |
|---|---|
| Sponsor | Fu Wai Hospital, Beijing, China |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Lipid-lowering drugs work through various mechanisms such as inhibiting HMG-CoA reductase (statins), inhibiting PCSK9 to increase LDL receptor clearance, or reducing triglyceride synthesis. These agents decrease circulating lipid levels, reducing atherosclerotic plaque formation and cardiovascular event risk.
Approved indications
- Hyperlipidemia
- Cardiovascular disease prevention
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes
- Gastrointestinal upset
Key clinical trials
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients
- Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction (NA)
- Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis (PHASE2)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC (PHASE1)
- Metformin Safety and Efficacy in Osteoarthritis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipid-lowering drug CI brief — competitive landscape report
- Lipid-lowering drug updates RSS · CI watch RSS
- Fu Wai Hospital, Beijing, China portfolio CI